20/20 Biolabs, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was One Test at $1.8 million, 88% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
|---|---|---|
| Revenue |
—
|
2
|
| One Test |
—
|
2
share 88.2%
|
| Bio Check |
—
|
0
share 7.4%
|
| CLI Ax |
—
|
0
share 4.4%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- AIDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1139685
- Former names
- 20/20 GeneSystems, Inc. (until Feb 26, 2025); 20/20 GENE SYSTEMS INC (until Apr 28, 2004)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- Neogenomics Inc NEO
- Hypha Labs, Inc. FUNI
Source: SEC EDGAR filings. This is company-reported data, not investment advice.